Posted by Michael Wonder on 10 Jul 2021
Bayer’s Kerendia (finerenone) receives U.S. FDA approval for treatment of patients with chronic kidney disease associated with type 2 diabetes
9 July 2021 - First and only non-steroidal mineralocorticoid receptor antagonist approved for adults with chronic kidney disease associated with type 2 diabetes.
Bayer announced today the U.S. FDA has approved Kerendia (finerenone), a first-in-class non-steroidal mineralocorticoid receptor antagonist indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction and hospitalisation for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus.
